The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

January 11, 2022

Amado J. Zurita-Saavedra, MD, discusses the potential benefits of augmenting therapy earlier on in the treatment of patients with newly diagnosed metastatic prostate cancer.

January 11, 2022

Srdan Verstovsek, MD, PhD, discusses the key objective of the phase 3 IMpactMF trial examining imetelstat in patients with myelofibrosis.

January 10, 2022

Bilal A. Siddiqui, MD, discusses the nuances of defining the characteristics of nonmetastatic castration-resistant prostate cancer.

January 07, 2022

Nitin Jain, MD, discusses the preliminary results from the phase 1 BALLI-01 study, which investigated UCART22, a genetically modified allogeneic T-cell therapy, in patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

January 05, 2022

Jan A. Burger, MD, PhD, discusses choosing frontline therapy in chronic lymphocytic leukemia.

January 04, 2022

Anil K. Sood, MD, provides insight into his approach toward the frontline maintenance treatment of women with advanced ovarian cancer.

January 03, 2022

Ravin Ratan, MD, MEd, discusses the steps that should be taken to diagnose desmoid tumors.

December 23, 2021

James P. Allison, PhD, permanently etched his legacy into immuno-oncology with the development of ipilimumab, work that helped him win a Giants of Cancer Care® award for Scientific Advances in 2014.

December 22, 2021

Amado J. Zurita-Saavedra, MD, discusses emerging frontline therapies in metastatic hormone-sensitive prostate cancer.

December 22, 2021

Naval Daver, MD, discusses he encouraging early data that has been reported with KO-539 and other menin inhibitors in acute myeloid leukemia, data presented with novel KO-539 combinations in this disease, and next steps for research.

December 20, 2021

Despite their rarity, the management of desmoid tumors has been an area of significant clinical change as the field has shifted away from aggressive surgical interventions to active surveillance and systemic therapies that are less morbid for patients.

December 20, 2021

Amado J. Zurita-Saavedra, MD, discusses the utilization of the antiandrogen agents apalutamide and enzalutamide in patients with metastatic hormone-sensitive prostate cancer.

December 17, 2021

Anil K. Sood, MD, discusses navigating frontline maintenance therapy in ovarian cancer.

December 17, 2021

Naval Daver, MD, discusses the next steps for menin inhibitors in acute myeloid leukemia.

December 16, 2021

Elise Nassif, MD, discusses the evolving standard of care for patients with soft tissue sarcoma and the benefits of early phase inclusion, as well as histotype testing for this population.

December 15, 2021

Preclinical evidence suggests that pairing KO-539 with targeted agents directed against BCL-2, BET, and CDK6 could result in superior efficacy against KMT2A-rearranged and NPM1-mutated acute myeloid leukemia.

December 15, 2021

Alexander J. Lazar, MD, PhD, discusses the current state of diagnosis and treatment in desmoid tumors.

December 14, 2021

Bilal A. Siddiqui, MD, discusses selecting between available antiandrogen agents in nonmetastatic castration-resistant prostate cancer.

December 13, 2021

Dr. Shah and Dr. Wang discuss the management of cytokine release syndrome and neurotoxicity, the referral process, and the need for academic and community collaboration for CAR T-cell therapy in hematologic malignancies.

December 12, 2021

The novel non-covalent BTK inhibitor pirtobrutinib showed promising preclinical efficacy in overcoming ibrutinib and venetoclax resistance, and in limiting cell growth and inducing apoptosis in mantle cell lymphoma.